company background image
SMMT

Summit Therapeutics NasdaqGM:SMMT Stock Report

Last Price

US$3.14

Market Cap

US$694.7m

7D

-2.8%

1Y

52.4%

Updated

04 Feb, 2023

Data

Company Financials

Summit Therapeutics Inc.

NasdaqGM:SMMT Stock Report

Mkt Cap: US$694.7m

SMMT Stock Overview

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.

SMMT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Summit Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Summit Therapeutics
Historical stock prices
Current Share PriceUS$3.14
52 Week HighUS$5.78
52 Week LowUS$0.66
Beta-1.0
1 Month Change-35.79%
3 Month Change204.85%
1 Year Change52.43%
3 Year Change88.02%
5 Year Change-70.38%
Change since IPO-69.48%

Recent News & Updates

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Recent updates

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

Shareholder Returns

SMMTUS BiotechsUS Market
7D-2.8%-0.8%1.7%
1Y52.4%4.4%-9.6%

Return vs Industry: SMMT exceeded the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: SMMT exceeded the US Market which returned -8.5% over the past year.

Price Volatility

Is SMMT's price volatile compared to industry and market?
SMMT volatility
SMMT Average Weekly Movement61.8%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: SMMT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 62% a week.

Volatility Over Time: SMMT's weekly volatility has increased from 34% to 62% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003108Bob Dugganhttps://www.summittxinc.com

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.

Summit Therapeutics Inc. Fundamentals Summary

How do Summit Therapeutics's earnings and revenue compare to its market cap?
SMMT fundamental statistics
Market CapUS$694.70m
Earnings (TTM)-US$86.65m
Revenue (TTM)US$956.00k

726.7x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SMMT income statement (TTM)
RevenueUS$956.00k
Cost of RevenueUS$0
Gross ProfitUS$956.00k
Other ExpensesUS$87.61m
Earnings-US$86.65m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.39
Gross Margin100.00%
Net Profit Margin-9,064.02%
Debt/Equity Ratio0%

How did SMMT perform over the long term?

See historical performance and comparison